|
1
Lermontova, N.N., Lukoyanov, N.V., Serkova, T.P., et al. Dimebon improves learning in animals with experimental Alzheimer’s disease. Bulletin of Experimental Biology and Medicine 129(6) 640-642 (2000).
2
Doody, R.S., Gavrilova, S.I., Sano, M., et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: A randomised, double-blind, placebo-controlled study. Lancet 372 207-215 (2008).
3
Wu, J., Li, Q., Bezprozvanny, I. Evaluation of dimebon in cellular model of Huntington’s disease. Molecular Neurodegeneration (2008).
4
Bachurin, S., Bukatina, E., Lermontova, N., et al. Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 939 425-435 (2001).
5
Lermontova, N.N., Redkozubov, A.E., Shevtsova, E.F., et al. Dimebon and tacrine inhibit neurotoxic action of β-amyloid in culture and block L-type Ca2+ channels. Bulletin of Experimental Biology and Medicine 132(5) 1079-1083 (2001).
6
Grigor'ev, V.V., Dranyi, O.A., Bachurin, S.O. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bulletin of Experimental Biology and Medicine 136(5) 474-477 (2003).
7
Bachurin, S.O., Shevtsova, E.P., Kireeva, E.G., et al. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993 334-344 (2003).
|